Navigation Links
Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Date:1/22/2008

Will oversee efforts to expand access to effective health solutions in

developing countries

SEATTLE, Jan. 22 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today that Dr. Rajeev Venkayya has joined the Global Health Program as director of Global Health Delivery. Dr. Venkayya is a medical doctor and former coordinator of U.S. government medical and public health efforts, including preparations for a potential influenza pandemic.

Dr. Venkayya will oversee the Gates Foundation's efforts to help expand the availability of, and access to, effective vaccines, drugs, and other health solutions in the developing world. He will also lead efforts to prepare for delivery of future health solutions.

"A number of important health interventions currently in late-stage development could be on the market in the next several years. We want to ensure that these life-saving solutions reach those who need them most," said Dr. Tachi Yamada, president of the foundation's Global Health Program. "Rajeev brings a wealth of experience as both a physician and senior health policy strategist, and we're fortunate to have him heading our efforts in this area."

The foundation's Global Health Delivery team coordinates late-stage development of foundation-funded health technologies and interventions through clinical trials and regulatory approval. The Delivery team also identifies ways to ensure adequate financing to purchase vaccines and drugs, strengthen health supply and distribution systems, address shortages of health workers, and increase public awareness about health.

"Every year, millions of people in poor countries die from preventable causes because they do not receive basic health services taken for granted in rich countries," Dr. Venkayya said. "I look forward to working with the foundation's grantees and partners to address this critical challenge."

Global Health Delivery is one of five teams i
'/>"/>

SOURCE Bill & Melinda Gates Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
2. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
3. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
6. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
7. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
10. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
11. Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ov.23/PRNewswire-FirstCall/--WoundManagementTechno...providerofspecialtymedicalproducts,announcedthatit...prehensivemanagementbusinessupdatetoillustratethed...9salesincreased33.5%to$102,926vs.Q32008salesof$77,...dto$3,327,892vs.Q32008shareholderequityof$(321,257...
(Date:11/23/2009)...v.23/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq...edbyitspartnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),w...intheongoingphase2btrialofRG7128,afirst-in-classnu...chronichepatitisCvirus(HCV)infection.Thedecisionwa...nitoringCommittee(DMC)ofallavailablesafetydatafrom...
(Date:11/23/2009)...ZER,Pa.,Nov.23/PRNewswire-FirstCall/--CeptionThera...y,andCephalon,Inc.(Nasdaq: CEPH )todayannouncedres...eslizumab)asatreatmentforpediatriceosinophilicesop...entintheco-primaryendpointsofchangesinesophagealeo...aindicatedthatpatientstreatedwithCINQUILshowedasta...
Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 1Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 2Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 3Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 4Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 5Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 6Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 7Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 8Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 9Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 10Impact of cannabis on bones changes with age study finds 54427 1Interventional radiology treatment for uterine fibroids 3A Safe nonsurgical option 54424 1Interventional radiology treatment for uterine fibroids 3A Safe nonsurgical option 54424 2Interventional radiology treatment for uterine fibroids 3A Safe nonsurgical option 54424 3
...ansdel,Pharmaceuticals, Inc. (OTC Bulletin Board: ...and Drug Administration,s ("FDA") review of its Ph...e 3 clinical program for its,novel topical cream b...),Ketotransdel(TM). Transdel Pharmaceuticals is a ...lopment and commercialization of non-invasive,topi...
...ular Structures Needed for siRNA ...8 Silence Therapeutics plc,(AIM:SLN) Europe,s lea...ments on two recent journal articles: Nature(1) "S...ssion by siRNA via TLR3" Mark E.,Kleinman, et. al....,siRNA/Liposome Complexes in Mice is Sequence-Inde...
Other Medicine Technology:Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program 2Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program 3Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 2Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 3Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 4
(Date:11/23/2009)...tlinker.comannouncesthatanewmarketresearchreportis...arketTrends ,, http://www.reportlinker.com/p...m_source=prnewswire&utm_medium=pr&utm_camp...uchasSARS,outbreakoffluandbioterrorismhavefurthere...entingthespreadofinfections.Allthesefactorshavecon...
(Date:11/23/2009)...the November issue of GIE: Gastrointestinal Endos...l of the American Society for Gastrointestinal End...found that Barrett,s esophagus was detected in six...ic screening. Also in this issue, two studies exam... France, in the largest single-center experience t...
(Date:11/23/2009)...eorgia is leading an initiative that could result ...ickle cell disease. , Morehouse University Scho...ers in the initiative that is enlisting primary ca...homes" for patients, changing how patients are tre... and seeking better prevention and treatment strat...
(Date:11/23/2009)... been a simple case for a New York auto accident a...arge. , New York (PRWEB) ...or New York auto accident attorneys passed to cr...e turned fatal., , , , ,According to the New Yor...hot and killed during a heated road-rage argument....
(Date:11/23/2009)...re/--XiotechCorporationtodayannouncedthatMasonGene...ragesystem,poweredbyIntelligentStorageElement(ISE(...,enablefuturegrowthanddeliversignificantcapitaland..., MasonGeneral,locatedinShelton,Wash.,wasratedone...ed-Rural"hospitalsin2008and2009foritssuperioruseof...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 2Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 3Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 4Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 2Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 3Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 4Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 5Health News:Initiative could result in paradigm shift in the care of sickle cell patients 2Health News:Initiative could result in paradigm shift in the care of sickle cell patients 3Health News:Initiative could result in paradigm shift in the care of sickle cell patients 4Health News:Initiative could result in paradigm shift in the care of sickle cell patients 5Health News:An Incident of Road Rage Turns Into Murder 2Health News:ISE Technology by Xiotech Helps Hospital Achieve Data Center Efficiency, Savings 2
...igher quality diets also associated with higher in... (HealthDay News) -- People with higher levels of ...but pay more for selecting foods that are less ene...abetes, cardiovascular disease and some forms of c...
... Data Presented at American Heart Association ATVB...e Volume and Fewer New Plaque Lesions in Treated P...VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ) today ...d tomography (MDCT) scans before and after six mon...
... COSTA MESA, Calif., May 1 Oxygen Biotherapeutics...that the company has filed a Cosmetic Product Ingr...(TM) Gel, its new Oxycyte(R)-based cosmetic produc...ep closer to bringing our first product to market,...
... - Therapy is medically-necessary for thousands of...ue to cystic fibrosis or other conditions - , , ... today announced that the U.S. Food and Drug Admin...ibrosis (CF) or other conditions. CREON(R) is the ...
... Revenue Up 28%, EPS Up 77% Over Prior Year , , N...ced financial results for its first quarter ended ...9, revenue increased 28.2% to $49.9 million, compa...come of $3.2 million or $0.12 per fully diluted sh...
... Full-Year 2009 Guidance Range Increased to $2.70 ..., May 1, 2009 AMERIGROUP Corporation (NYSE: AGP...st quarter of 2009 increased 9.7% to $36.9 million...hlights include: , , , , Membership in...
Other Medicine News:Health News:More Educated Choose Healthier Foods, But Pay More 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 3Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 4Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 5Health News:Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel 2Health News:Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel 3Health News:Video: CREON(R) (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines 2Health News:Video: CREON(R) (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines 3Health News:Video: CREON(R) (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines 4Health News:Video: CREON(R) (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines 5Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 2Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 3Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 4Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 5Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 6Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 7Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 8Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 9Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 10Health News:HMS Holdings Corp. Announces First Quarter 2009 Financial Results 11Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 2Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 3Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 4Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 5Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 6Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 7Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 8Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 9Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 10Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 11Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 12Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 13Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 14Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 15
SMZ-660
SMZ-645
SMZ-1500
Achroplan Wasser objectives
Medicine Products: